tldrdaily.news logo
Tag

Bladder Cancer

All articles tagged with #bladder cancer

Colorblindness May Obscure Bladder Cancer Clues and Raise Mortality Risk
health27 days ago

Colorblindness May Obscure Bladder Cancer Clues and Raise Mortality Risk

Stanford Medicine analyzed large electronic health records via the TriNetX platform and found colorblind individuals diagnosed with bladder cancer had a 52% higher risk of death over 20 years compared with color-normal patients, likely due to delayed detection of blood in urine. The effect was not seen for colorectal cancer. The study suggests clinicians consider color vision differences in screening and encourage urine testing when suspicion arises; the researchers note possible undercounting and call for further investigation.

via SciTechDaily|
#bladder-cancer#cancer-survival#color-vision-deficiency
Colorblindness Linked to Higher Bladder Cancer Mortality, Study Finds
health29 days ago

Colorblindness Linked to Higher Bladder Cancer Mortality, Study Finds

A Stanford-led analysis of electronic health records found colorblind individuals diagnosed with bladder cancer had a 52% higher risk of death over 20 years compared with non-colorblind patients, possibly because they don’t notice blood in urine—the key early sign—while no mortality difference was observed for colorectal cancer. The authors stress this is hypothesis-generating and call for further research and awareness about diagnostic cues and potential screening considerations for color vision deficiency.

via Gizmodo|
#bladder-cancer#cancer-mortality#colorblindness
ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA
markets1 month ago

ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA

ImmunityBio (IBRX) shares rose about 26% after the FDA outlined a potential resubmission path for ANKTIVA in BCG-unresponsive papillary non-muscle invasive bladder cancer, saying additional information is needed to support a supplemental Biologics License Application but no new clinical trials are required, a development investors view as de-risking the regulatory process and potentially enabling a broader label. Trading volume surged on Nasdaq amid the regulatory update and ongoing volatility around ANKTIVA’s commercialization prospects.

via Nasdaq|
#anktiva#bladder-cancer#fda
biotechnology1 month ago

ImmunityBio Pursues FDA Path to Resubmission for ANKTIVA in Papillary NMIBC

ImmunityBio announced a productive Type B End‑of‑Phase meeting with the FDA regarding its supplemental Biologics License Application for ANKTIVA plus BCG in BCG‑unresponsive papillary NMIBC. The FDA asked for additional information (not new trials) to support a potential resubmission, which ImmunityBio will provide within 30 days. Long‑term QUILT‑3.032 data in 80 patients show about 96% bladder cancer‑specific survival at 36 months and high cystectomy‑free survival (roughly 82–93% at 12–36 months), underscoring a bladder‐sparing, chemo‑free approach. ANKTIVA is already approved for CIS in the US, UK, and Saudi Arabia, with EU conditional status for CIS and ongoing EMA discussions to extend labeling to papillary disease if US approval is achieved.

via Business Wire|
#antkiva#biotechnology#bladder-cancer
KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients
healthcare2 months ago

KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients

Merck announced positive results from the Phase 3 KEYNOTE-B15 trial showing that combining KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) before and after surgery significantly improves survival and response rates in cisplatin-eligible muscle-invasive bladder cancer patients, with a safety profile consistent with known effects.

via Merck.com|
#bladder-cancer#clinical-trial#healthcare
Innovative Treatment Achieves 82% Success in Bladder Cancer Cure
health3 months ago

Innovative Treatment Achieves 82% Success in Bladder Cancer Cure

A new implant called TAR-200 has shown promising results in a phase 2 trial, eliminating tumors in 82% of high-risk bladder cancer patients resistant to previous treatments, with most tumors disappearing within three months and many patients remaining cancer-free after a year, offering a potentially safer and more effective alternative to traditional therapies.

via ScienceDaily|
#bladder-cancer#cancer-treatment#clinical-trial
Innovative Treatment Achieves Over 80% Success in Bladder Cancer Eradication
health6 months ago

Innovative Treatment Achieves Over 80% Success in Bladder Cancer Eradication

A new bladder cancer treatment using the TAR-200 device, which delivers chemotherapy directly into the bladder, has shown promising results with 82% of patients experiencing cancer disappearance after three months, and nearly half remaining cancer-free after a year, representing a significant breakthrough in treatment options.

via Good News Network|
#bladder-cancer#cancer-treatment#chemo-delivery
Innovative Pretzel-Shaped Implant Cures 82% of Bladder Cancer Patients
health6 months ago

Innovative Pretzel-Shaped Implant Cures 82% of Bladder Cancer Patients

A new pretzel-shaped implant called TAR-200, containing chemotherapy drug gemcitabine, has shown promising results in eradicating bladder cancer in over 80% of patients, especially those with carcinoma in situ, by releasing the drug steadily over three weeks. The device, which is less invasive than surgery, has demonstrated higher response rates than existing treatments and is currently under FDA review, potentially revolutionizing bladder cancer therapy.

via ZME Science|
#bladder-cancer#cancer-treatment#chemotherapy